News

The Motley Fool: Merck’s risks and potential
There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could ...
Medical Dialogues7h
Merck Keytruda approved by USFDA for Advanced Head and Neck Cancer
Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...
Merck Stock’s Ticking Keytruda Time Bomb
However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...
News-Medical.Net on MSN1d
Benchling and Merck collaborate on vaccine bioanalysis
Benchling announced a new collaboration with Merck, known as MSD outside of the United States and Canada, to implement a ...
Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda
Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...
Fierce Biotech6d
Merck's leader in oral PCSK9 inhibitor race reduces cholesterol in pair of phase 3 trials
Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...
Explore more
Merck's potential blockbuster cholesterol pill succeeds in late-stage studies
Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery
Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...
Citizens Financial, Merck, oil producers: Trending Tickers
Citizens Financial Group (CFG) will be expanding its share buyback program to $1.5 billion. Pharmaceutical giant Merck (MRK) ...
Merck Wins US Approval for Shot to Prevent Infant RSV
Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...
Medical Dialogues2d
Merck begins Phase 3 study for Dengue vaccine candidate
Merck is establishing a program of clinical trials for V181, including conducting trials globally, in places where dengue is ...